Previous 10 | Next 10 |
home / stock / dskyf / dskyf news
Dr_Microbe/iStock via Getty Images Today's up to $3B development and commercialization deal from Bristol-Myers Squibb (BMY) for Eisai's (ESALY) for MORAb-202 is putting antibody drug conjugates ("ADCs"), which some feel is the future of cancer therapeutics, into the spotlight. The o...
Delmaine Donson/E+ via Getty Images If this morning's announcement from Bristol-Myers Squibb (BMY) for up to $3B for development and commercialization of Eisai's (ESALY) MORAb-202 antibody drug conjugate sounds familiar, you're right. Back in March 2019, AstraZeneca (AZN) and Daiichi San...
loops7/E+ via Getty Images Daiichi Sankyo (DSNKY) is ending development of nafamostat as a potential therapy for COVID-19, Reuters reports. The Japanese drugmaker did not give a reason for abandoning the program. However, Japan's Nikkei newspaper said there were safety concerns. Nafamostat is...
AstraZeneca's innovative culture earned it a place as one of the leading biotechs globally. Revenue growth from COVID vaccine sales and some key markets provide strong tailwinds for the company's share in the second half of 2021. Most of AstraZeneca's revenue comes from a handful ...
Daiichi Sankyo Company Limited (DSKYF) Q4 2020 Earnings Conference Call April 27, 2021 3:00 AM ET Company Participants Sunao Manabe - President and CEO Wataru Takasaki - Head, R&D Division Hiroyuki Okuzawa - Head of Corporate Planning & Management Division and CFO Conference Call Part...
The following slide deck was published by Daiichi Sankyo Company, Limited in conjunction with their 2020 Q4 earnings call. For further details see: Daiichi Sankyo Company, Limited 2020 Q4 - Results - Earnings Call Presentation
Guardant Health (GH) collaborates with Daiichi Sankyo (DSKYF) to pursue regulatory approval and commercialization of the Guardant360 CDx blood test as a companion diagnostic for Enhertu being studied in the treatment of advanced metastatic non-small cell lung cancer ((NSCLC)). The Guarda...
LogicBio Therapeutics (LOGC) has added ~10.0% in the pre-market after announcing two separate collaborations with CANbridge Pharmaceuticals and Daiichi Sankyo (DSKYF).Under the terms of strategic collaboration and option agreements with CANbridge, the company has granted t...
Daiichi Sankyo (DSKYF): FY GAAP EPS of ¥39.11.Revenue of ¥962.51B (-2.0% Y/Y)Press Release For further details see: Daiichi Sankyo reports FY 2020 results
Esperion Therapeutics (ESPR) has signed a new licensing agreement granting the exclusive rights to Daiichi Sankyo Company (DSKYF) to commercialize bempedoic acid and the bempedoic acid/ezetimibe combination tablet in additional countries.The deal allows Daiichi Sankyo to commercialize th...
News, Short Squeeze, Breakout and More Instantly...
Daiichi Sankyo Co Ltd Company Name:
DSKYF Stock Symbol:
OTCMKTS Market:
Publication highlights Europe -specific one-year follow-up findings for atrial fibrillation (AF) patients in routine clinical practice, in which, rates of stroke, systemic embolism, and major bleeding are considered by the authors to be low in edoxaban treated patients [1] Findings...
· Results published in the European Heart Journal – Cardiovascular Pharmacotherapy , showed rates of thromboembolism similar to those observed in the ENGAGE AF-TIMI 48 clinical trial [1] · Study reports LIXIANA outcomes from one of the largest observational ...
- ENTRUST-AF PCI study achieved the primary safety endpoint of non-inferiority in bleeding for edoxaban-based dual therapy compared with VKA-based triple antithrombotic therapy (using a risk-based duration of ASA for at least one month) in AF patients following stent placement - ...